<DOC>
	<DOCNO>NCT03100045</DOCNO>
	<brief_summary>This open label study investigate novel non-surgical approach treatment HPV-associated anal intraepithelial neoplasia , use Artesunate suppository .</brief_summary>
	<brief_title>Intra-Anally Administered Artesunate Patients With High-Grade Anal Intraepithelial Neoplasia ( AIN 2/3 )</brief_title>
	<detailed_description>Patients diagnose AIN 2/3 enrol sequentially treatment cohort receive different dos Artesunate suppository administer trans-anally . Doses escalation 200 mg , 400 mg , 600 mg . Treatment cohort consist 2 3 cycle dose level . Suppositories administer daily 5 day . Five day constitute 1 cycle . Up 3 cycle administer Weeks 0 , 2 , 4 .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Artemisinine</mesh_term>
	<criteria>Age ≥ 18 year Biopsyconfirmed highgrade anal dysplasia ( AIN 2 , AIN 3 , HSIL ) high resolution anoscopy ( HRA ) Female childbearing potential : negative urine pregnancy test Able provide inform consent Patients ability collaborate plan followup ( transportation , compliance history , etc. ) . Weight ≥50 kg . Diagnosis lowgrade anal dysplasia ( AIN 1 , LSIL ) high resolution anoscopy Known anal , vulvar , cervical , penile cancer CD4 count &lt; 200 time consideration entry study Unable provide inform consent Currently receive systemic chemotherapy radiation therapy another cancer . Patients medical treatment systemic immunosuppressant steroid ( e.g. , active autoimmune disease ) Extensive anal condyloma precludes ability clinician visualize HSIL HRA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>HPV</keyword>
	<keyword>suppository</keyword>
	<keyword>Artesunate</keyword>
	<keyword>artemisinin</keyword>
	<keyword>anal dysplasia</keyword>
	<keyword>treatment</keyword>
	<keyword>alternative treatment</keyword>
	<keyword>anal precancer</keyword>
	<keyword>Johns Hopkins</keyword>
	<keyword>Sandy Fang</keyword>
	<keyword>Frantz Viral Therapeutics</keyword>
</DOC>